H.R.3723 - Medical Device Electronic Labeling Act.
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Issues related to Medicare coverage for breakthrough medical devices.
Issues related to AI in health care.
Duration: July 1, 2010
to
present
General Issues: Health Issues , Medicare/Medicaid , Consumer Issues/Safety/Protection , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code , Transportation , Defense , Copyright/Patent/Trademark , Budget/Appropriations , Veterans , Immigration
Spending: about $2,120,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2010: House of Representatives, U.S. Senate, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Office of Management & Budget (OMB), U.S. Senate,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Darren Willcox
Asst for Policy, Speaker Dennis Hastert
Admin Asst; Leg Dir; Leg Asst, Cong. Porter Goss
House Rules Comm Assoc, Subcomm Staff Dir.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on April 22.
Original Filing: 301575611.xml
Lobbying Issues
H.R.3723 - Medical Device Electronic Labeling Act.
Lobbying Issues
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Issues related to Medicare coverage for breakthrough medical devices.
Issues related to AI in health care.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Jan. 22.
Original Filing: 301537281.xml
Lobbying Issues
H.R.3723 - Medical Device Electronic Labeling Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Issues related to Medicare coverage for breakthrough medical devices.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511962.xml
Lobbying Issues
H.R.3723 - Medical Device Electronic Labeling Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Issues related to Medicare coverage for breakthrough medical devices.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301489682.xml
Lobbying Issues
Implementation of P.L. 117-328 regarding device change control plans.
H.R.3723 - Medical Device Electronic Labeling Act 1.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Issues related to Medicare coverage for breakthrough medical devices.
Issues related to Medicare coverage of digital health technologies.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on April 20, 2023.
Original Filing: 301467260.xml
Lobbying Issues
Implementation of P.L. 117-328 regarding device change control plans.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare coverage for breakthrough medical devices.
Issues related to Medicare coverage of digital health technologies.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Jan. 20, 2023.
Original Filing: 301436640.xml
Lobbying Issues
21st Century Cures 2.0.
H.R.1193: Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act.
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
H.R.7084: PATCH Act of 2022.
H.R.9067: Better Interoperability for Devices (BID) Act.
S.3799 - PREVENT Pandemics Act.
S.4391 - CLEAR Documentation Act - regarding certificates to foreign government.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2022
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413362.xml
Lobbying Issues
21st Century Cures 2.0.
H.R.1193: Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act.
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
H.R.7084 - PATCH Act of 2022.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Artificial Intelligence and other Emerging Technologies.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
2nd Quarter, 2022
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on July 19, 2022.
Original Filing: 301386195.xml
Lobbying Issues
21st Century Cures 2.0.
H.R.1193: Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act.
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Artificial Intelligence and other Emerging Technologies.
Type of Issue
Consumer Issues/Safety/Protection
1st Quarter, 2022
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on April 20, 2022.
Original Filing: 301371463.xml
Lobbying Issues
CMS Medicare Coverage and Reimbursement for innovative new technologies including Artificial Intelligence.
FY '22 CMS Inpatient Rule.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
21st Century Cures 2.0.
H.R.1193: Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act.
Reauthorization of the Medical Device User Fee Act and related issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Artificial Intelligence and other Emerging Technologies.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
4th Quarter, 2021
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Jan. 20, 2022.
Original Filing: 301333901.xml
Lobbying Issues
CMS Medicare Coverage of Breakthrough Medical Devices.
FY '22 CMS Inpatient Rule.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
21st Century Cures 2.0.
H.R.5558: Prostate Cancer Prevention Act.
H.R.1193: Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Artificial Intelligence and other Emerging Technologies.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2021
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Oct. 20, 2021.
Original Filing: 301310210.xml
Lobbying Issues
CMS Medicare Coverage of Breakthrough Medical Devices.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Artificial Intelligence and other Emerging Technologies.
Issues related to privacy.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
2nd Quarter, 2021
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on July 20, 2021.
Original Filing: 301284065.xml
Lobbying Issues
CMS Medicare Coverage of Breakthrough Medical Devices.
CY 2021 DMEPOS rule as it relates to Continuous Glucose Monitors.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Artificial Intelligence and other Emerging Technologies.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
1st Quarter, 2021
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on April 19, 2021.
Original Filing: 301258175.xml
Lobbying Issues
CMS Medicare Coverage Innovative Technology Rule.
CY 2021 DMEPOS rule as it relates to Continuous Glucose Monitors.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Jan. 20, 2021.
Original Filing: 301238624.xml
Lobbying Issues
Administrations Proposed Rule on Safe Harbors/Anti-Kickback Statute.
H.R.133: Consolidated Appropriations Act, 2021.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to Medicare coverage of breakthrough medical devices including, H.R.5333: Ensuring Patient Access to Critical Breakthrough Products Act of 2019.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222688.xml
Lobbying Issues
Administrations Proposed Rule on Safe Harbors/Anti-Kickback Statute.
Issues related to and legislation around remote patient monitoring with respect to COVID-19.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to global supply chains.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2020
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on July 20, 2020.
Original Filing: 301201694.xml
Lobbying Issues
Administrations Proposed Rule on Safe Harbors/Anti-Kickback Statute.
Issues related to and legislation around remote patient monitoring.
Draft legislation around 21st Century Cures 2.0.
Agencies Lobbied
U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to global supply chains.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2020
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on April 20, 2020.
Original Filing: 301176813.xml
Lobbying Issues
"Shared Accountability for Improved Patient Outcomes Act of 2018," "PAVE Act", and other education related to value based healthcare arrangements.
Administrations Proposed Rule on Safe Harbors/Anti-Kickback Statute.
Issues related to medical devices and COVID-19.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Office of Management & Budget (OMB)
Lobbying Issues
H.R.5333: Ensuring Patient Access to Critical Breakthrough Products Act of 2019.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Federal data privacy legislation.
Type of Issue
Consumer Issues/Safety/Protection
4th Quarter, 2019
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128919.xml
Lobbying Issues
"Shared Accountability for Improved Patient Outcomes Act of 2018," "PAVE Act", and other education related to value based healthcare arrangements.
Administrations Proposed Rule on Safe Harbors/Anti-Kickback Statute.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
H.R.1865, FY 2020 Appropriations as it relates to H.R.2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to breakthrough medical technologies.
Issues related to continuous glucose monitoring systems.
Agencies Lobbied
U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Federal data privacy legislation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2019
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078483.xml
Lobbying Issues
"Shared Accountability for Improved Patient Outcomes Act of 2018," "PAVE Act", and other education related to value based healthcare arrangements.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to breakthrough medical technologies.
Issues related to continuous glucose monitoring systems.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Federal data privacy legislation.
Type of Issue
Consumer Issues/Safety/Protection
2nd Quarter, 2019
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on July 22, 2019.
Original Filing: 301056834.xml
Lobbying Issues
"Shared Accountability for Improved Patient Outcomes Act of 2018," and other education related to value based healthcare arrangements.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to breakthrough medical technologies.
Issues related to continuous glucose monitoring systems.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2019
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on April 22, 2019.
Original Filing: 301035205.xml
Lobbying Issues
"Shared Accountability for Improved Patient Outcomes Act of 2018," and other education related to value based healthcare arrangements.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015978.xml
Lobbying Issues
H.R.7122: Shared Accountability for Improved Patient Outcomes Act of 2018, and other education related to value based healthcare arrangements.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4617: Protect Medical Innovation Act.
H.R.88 as it relates to the medical device tax.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2018
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Oct. 22, 2018.
Original Filing: 300994766.xml
Lobbying Issues
Education about the importance of value based health care and innovative contracting.
H.R.6: Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act as it relates to provisions designed to promote the importance of non-pharmacological pain treatment options, including medical devices.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.4617: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare policies on continuous glucose monitoring.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on July 20, 2018.
Original Filing: 300975770.xml
Lobbying Issues
Education about the importance of value based health care and innovative contracting.
H.R.6: Support for Patients and Communities Act as it relates to provisions designed to promote the importance of non-pharmacological pain treatment options, including medical devices.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.4617: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare coverage and reimbursement for insulin pumps.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on April 20, 2018.
Original Filing: 300956901.xml
Lobbying Issues
Education about the importance of value based health care and innovative contracting.
Education about the importance of non-pharmacological pain treatment options, including medical devices.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FY 2018 Continuing resolution as it relates to suspension of the medical device tax.
H.R.4617: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2017
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929409.xml
Lobbying Issues
Education about the importance of value based health care.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1/S.1: Tax Cuts and Jobs Act.
H.R.4617: To amend the Internal Revenue Code of 1986 to provide for a temporary moratorium on the medical device excise tax.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Oct. 20, 2017.
Original Filing: 300916149.xml
Lobbying Issues
Issues related to Medicare DME Competitive Bidding as it relates to insulin pumps.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Lobbying Issues
H.R.1628: American Health Care Act and Better Care Reconciliation Act of 2017 (BCRA), as it relates to the medical device tax.
Education about the importance of value based health care.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2017
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on July 20, 2017.
Original Filing: 300897342.xml
Lobbying Issues
Issues related to Medicare DME Competitive Bidding as it relates to insulin pumps.
Agencies Lobbied
U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
H.R.1628: American Health Care Act, as it relates to the medical device tax.
Education about the importance of value based health care.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2017
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on April 20, 2017.
Original Filing: 300876731.xml
Lobbying Issues
Issues related to Medicare DME Competitive Bidding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1628: American Health Care Act, as it relates to the medical device tax.
Education about the importance of value based health care.
Reauthorization of the Medical Device User Fee Act (MDUFA).
Education about FDA regulation of morcellators.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2016
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Jan. 23, 2017.
Original Filing: 300855329.xml
Lobbying Issues
H.R. 1427: Medicare CGM Access Act of 2014.
H.R. 5210: Patient Access to DME Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the importance of value based health care.
Education about FDA regulation of morcellators.
H.R. 34: 21st Century Cures Act Conference Report.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2016
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Oct. 20, 2016.
Original Filing: 300838975.xml
Lobbying Issues
H.R. 1427: Medicare CGM Access Act of 2014.
H.R. 5210: Patient Access to DME Act.
Issues related to Unique Device Identifiers and Medical Claims.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the importance of value based health care.
Education about FDA regulation of morcellators.
Issues related to Medical Device User Fee Reauthorization.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2016
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on July 20, 2016.
Original Filing: 300819783.xml
Lobbying Issues
H.R. 1427: Medicare CGM Access Act of 2014.
H.R. 5210: Patient Access to DME Act.
Issues related to Unique Device Identifiers and Medical Claims.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the importance of value based health care.
Issues related to Medical Device User Fee Reauthorization.
S. 524: Comprehensive Addiction and Recovery Act of 2016.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2017 National Defense Authorization Act.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2016
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on April 20, 2016.
Original Filing: 300803070.xml
Lobbying Issues
H.R. 1427: Medicare CGM Access Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Provided continuing support for Medtronic acquisition of Covidien, including potential legislation on federal contracting limitations and other tax policy proposals.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to disruptive innovations like 3D printing in health care.
Education about the importance of value based health care.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1927: "Fairness in Class Action Litigation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2015
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Jan. 19, 2016.
Original Filing: 300776330.xml
Lobbying Issues
H.R. 1427: Medicare CGM Access Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Provided continuing support for Medtronic acquisition of Covidien, including potential legislation on federal contracting limitations and other tax policy proposals.
Issues related to corporate tax reform, including international tax issues.
P.L. 114-113: "Consolidated Appropriations Act" with respect to the Protecting Americans from Tax Hikes Act and provisions related to delay in the medical device tax.
H.R. 160: Protect Medical Innovation Act of 2016.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6: 21st Century Cures Act, including potential changes to post market medical device registries and Medicaid reimbursement for DMEPOS.
James Zadroga 9/11 Health and Compensation Reauthorization as it relates to offsets impacting DMEPOS in Medicaid.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2015
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763660.xml
Lobbying Issues
H.R. 1427: Medicare CGM Access Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Provided continuing support for Medtronic acquisition of Covidien, including potential legislation on federal contracting limitations and other tax policy proposals.
Issues related to corporate tax reform, including international tax issues.
H.R. 160: Protect Medical Innovation Act of 2016.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6: 21st Century Cures Act, including potential changes to post market medical device registries and Medicaid reimbursement for DMEPOS.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2015
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on July 20, 2015.
Original Filing: 300743519.xml
Lobbying Issues
H.R. 1427: Medicare CGM Access Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Provided continuing support for Medtronic acquisition of Covidien, including potential legislation on federal contracting limitations and other tax policy proposals.
Issues related to corporate tax reform, including international tax issues.
H.R. 160: Protect Medical Innovation Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6: 21st Century Cures Act, including potential changes to post market medical device registries and Medicaid reimbursement for DMEPOS.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2015
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on April 20, 2015.
Original Filing: 300727649.xml
Lobbying Issues
H.R. 1427: Medicare CGM Access Act of 2014.
H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Provided continuing support for Medtronic acquisition of Covidien, including potential legislation on federal contracting limitations and other tax policy proposals.
Issues related to corporate tax reform, including international tax issues.
H.R. 160: Protect Medical Innovation Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Issues related to remote patient management and telehealth.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2014
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on Jan. 20, 2015.
Original Filing: 300704094.xml
Lobbying Issues
Education on issues related to coverage of continuous glucose monitoring devices and DME MAC coding decisions related to Medicare coverage of CGM supplies.
H.R. 5644: Medicare CGM Access Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2360/H.R. 4679: Stop Corporate Inversions Act of 2014.
Provided continuing support for Medtronic acquisition of Covidien, including legislation on federal contracting limitations.
H.R. 5771: Tax Increase Prevention Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3303: SOFTWARE Act of 2013.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3547: Consolidated Appropriations Act for FY 2015.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on Oct. 17, 2014.
Original Filing: 300684864.xml
Lobbying Issues
Educated leadership of the House Diabetes Caucus on issues related to coverage of continuous glucose monitoring devices.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2360/H.R. 4679: Stop Corporate Inversions Act of 2014.
Information sharing regarding the June 15, 2014 announcement by Medtronic that the company entered into a definitive agreement to acquire healthcare technology and medical supplies provider Covidien.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3303: SOFTWARE Act of 2013.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on July 21, 2014.
Original Filing: 300665010.xml
Lobbying Issues
Educated leadership of the House Diabetes Caucus on issues related to coverage of continuous glucose monitoring devices.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2360/H.R. 4679: Stop Corporate Inversions Act of 2014.
Information sharing regarding the June 15, 2014 announcement by Medtronic that the company entered into a definitive agreement to acquire healthcare technology and medical supplies provider Covidien.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. 1720: Patent Transparency and Improvements Act.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 3303: SOFTWARE Act of 2013.
FDA reclassification of medical devices.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Trade agreement processes and procedures.
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2014
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on April 15, 2014.
Original Filing: 300645477.xml
Lobbying Issues
H.R. 4302: Protecting Access to Medicare Act of 2014.
Educated leadership of the House Diabetes Caucus on issues related to coverage of continuous glucose monitoring devices.
H.R. 3303: SOFTWARE Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523: Protect Medical Innovation Act of 2013 - provisions relating to the repeal of the medical device excise tax.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3309: Innovation Act.
S. 1720: Patent Transparency and Improvements Act.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to procurement by the Veterans Administration.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on Jan. 14, 2014.
Original Filing: 300621925.xml
Lobbying Issues
H.R. 2810, S: Medicare Patient Access and Quality Improvement Act of 2013.
Educated leadership of the House Diabetes Caucus on issues related to coverage of continuous glucose monitoring devices.
Education about innovation with respect to Renal Derivation Devices as well as CMS/FDA parallel review.
Issues related to CMMI (Center of Medicare and Medicaid Innovation).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to immigration reform and its treatment of skilled worker visas.
H.R. 2131: SKILLS Visa Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523: Protect Medical Innovation Act of 2013 - provisions relating to the repeal of the medical device excise tax.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored draft patent reform legislation.
H.R. 3309: Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to procurement by the Veterans Administration.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.J. Res. 59 The Bipartisan Budget Act of 2013 Public Law No: 113-067.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.3303: SOFTWARE Act of 2013.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on Oct. 18, 2013.
Original Filing: 300601823.xml
Lobbying Issues
Monitored draft legislation to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
Educated leadership of the House Diabetes Caucus on issues related to coverage of continuous glucose monitoring devices.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to immigration reform and its treatment of skilled worker visas.
H.R. 2131: SKILLS Visa Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523: Protect Medical Innovation Act of 2013 - provisions relating to the repeal of the medical device excise tax.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored draft patent reform legislation.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2013
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on July 19, 2013.
Original Filing: 300577257.xml
Lobbying Issues
Legislation to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to immigration reform and its treatment of skilled worker visas.
H.R. 2131: SKILLS Visa Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523: Protect Medical Innovation Act of 2013 - provisions relating to the repeal of the medical device excise tax.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on April 18, 2013.
Original Filing: 300558914.xml
Lobbying Issues
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education on reimbursement of medical devices in India.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to immigration reform and its treatment of skilled worker visas.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on Jan. 20, 2013.
Original Filing: 300542508.xml
Lobbying Issues
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care Act - Provisions relating to physician payment disclosure.
Lobbying Issues
Issues relating to Russia PNTR.
H.R. 6156: Russia and Moldova Jackson-Vanik Repeal and Sergei Magnitsky Rule of Law Accountability Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2012
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on Oct. 16, 2012.
Original Filing: 300512556.xml
Lobbying Issues
P.L.112 - 25, Budget Control Act, as it relates to sequestration of Medicare and FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care Act - Provisions relating to physician payment disclosure.
P.L. 112-144, The Food and Drug Administration Safety and Innovation Act of 2012, as it relates to approval of medical devices.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to Russia PNTR.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.J.Res. 117: Continuing Appropriations Resolution for Fiscal Year 2013.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $30,000. The report was filed on July 16, 2012.
Original Filing: 300489932.xml
Lobbying Issues
H.R. 5651: Food and Drug Administration Reform Act of 2012 and S. 3187: Food and Drug Administration Safety and Innovation Act of 2012 as they relate to medical devices.
H.R. 3211: Humanitarian Device Reform Act of 2011 - Provisions relating to the improving of humanitarian device regulation and foster device development for rare diseases.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to Russia PNTR.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2012
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on April 18, 2012.
Original Filing: 300464049.xml
Lobbying Issues
FDA legislation related to reform of the approval process for medical devices.
H.R. 3211: Humanitarian Device Reform Act of 2011 - Provisions relating to the improving of humanitarian device regulation and foster device development for rare diseases.Implementation of the Physician Sunshine Act.
H.R. 3630 Middle Class Tax Relief and Job Creation Act of 2012 (formerly the Temporary Payroll Tax Cut Continuation Act of 2011).
H.R. 3209 - Premarket Predictability Act of 2011 - Provisions relating to a new streamlined review of new devices, require reviewers to provide scientific or regulatory rationale for major decisions and establish an expedited approval appellate process, and the establishment of the two Investigational Device Exemption pathways.
H.R. 3203 - Novel Device Regulatory Relief Act of 2011 - Streamlines the de novo classification process by striking the requirement that an applicant submit a 510(k) application before entering the de novo process.
H.R. 3206 - Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011 - Fixes the FDA's conflict of interest policies to ensure the most knowledgeable experts are able to serve on FDA advisory committees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 5: Help efficient, Accessible, Low-cost, Timely Healthcare Act - Provisions relating to the repeal of the Medicare Independent Payment Advisory Board.
H.R. 452: Medicare Decisions Accountability Act - provisions relating to the repeal of the Medicare Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 233: FAA Air Transportation Modernization and Safety Improvement Act of 2012 - Issues related to regulation of transporting lithium batteries.
4th Quarter, 2011
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Jan. 19, 2012.
Original Filing: 300445650.xml
Lobbying Issues
FDA legislation related to reform of the approval process for medical devices.
H.R. 3211: Humanitarian Device Reform Act of 2011.
Implementation of the Physician Sunshine Act.H.R. 3209 - Premarket Predictability Act of 2011 - Provisions relating to a new streamlined review of new devices, require reviewers to provide scientific or regulatory rationale for major decisions and establish an expedited approval appellate process, and the establishment of the two Investigational Device Exemption pathways.
H.R. 3203 - Novel Device Regulatory Relief Act of 2011 - Streamlines the de novo classification process by striking the requirement that an applicant submit a 510(k) application before entering the de novo process.
H.R. 3206 - Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011 - Fixes the FDA's conflict of interest policies to ensure the most knowledgeable experts are able to serve on FDA advisory committees.
H.R. 3214 - Food and Drug Amdinistration Mission Reform Act of 2011 - establishes a regulatory system that is accessible, consistent and transparent, promotes predictability, allows flexibility and reduces uncertainty, facilitates innovation, protects public health and enables patients accessto novel products, and incorporates a patient-focused, risk-benefit framework to ensure the FDA takes them into account.
H.R. 3205 - FDA Renewing Efficiency From Outside Reviewer Management Act of 2011 - Reauthorizes the third party inspection program and reforms the third party review program to foster better participation, decrease approval times and conserve FDA resources.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
3rd Quarter, 2011
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $40,000. The report was filed on Oct. 20, 2011.
Original Filing: 300424134.xml
Lobbying Issues
Humanitarian Device Reform legislation to foster device development for rare diseases.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Amendment to the FAA reauthorization bill (H.R. 658) prohibiting the promulgation of regulations related to lithium batteries.
Lobbying Issues
P.L. 112-25 - The Budget Control Act of 2011 as it relates to Medicare reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, W Strategies, LLC lobbied for Medtronic, Inc. , earning $50,000. The report was filed on July 17, 2011.
Original Filing: 300399051.xml
Lobbying Issues
FDA legislation and Executive Branch action related to reform of the 510(k) approval process for medical devices.
S. 17 - Medical Device Access and Innovation Act.
H.R. 436 - Protect Medical Device Innovation Act.
Outreach and education to repeal the Independent Payment Advisory Board.H.R. 452 - Medicare Decisions Accountability Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Amendment to the FAA reauthorization bill (H.R. 658) prohibiting the promulgation of regulations related to lithium batteries.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, W Strategies, LLC lobbied for Medtronic, Inc. , earning $50,000. The report was filed on April 16, 2011.
Original Filing: 300370082.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research.
FDA legislation and Executive Branch action related to reform of the 510(k) approval process for medical devices.
S. 17 - Medical Device Access and Innovation Act.H.R. 436 - Protect Medical Device Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
CMS coverage of pacemakers and MRI's.
H.R. 675 - "To expand the permissive exclusion from participation in federal health care programs to individuals and entities affiliated with sanctioned entities."
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Amendment to the FAA reauthorization bill (H.R. 658) prohibiting the promulgation of regulations related to lithium batteries.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, W Strategies, LLC lobbied for Medtronic, Inc. , earning $50,000. The report was filed on Jan. 12, 2011.
Original Filing: 300346630.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research.
FDA legislation and Executive Branch action related to reform of the 510(k) approval process for medical devices.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
3rd Quarter, 2010
In Q3, W Strategies, LLC lobbied for Medtronic, Inc. , earning $50,000. The report was filed on Oct. 15, 2010.
Original Filing: 300321353.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research.
FDA legislation and Executive Branch action related to reform of the 510(k) approval process for medical devices.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
3rd Quarter, 2010
W Strategies, LLC filed a lobbying registration on Aug. 9, 2010 to represent Medtronic, Inc., effective July 1, 2010.
Original Filing: 300306743.xml
Issue(s) they said they’d lobby about: FDA legislation and Executive Branch action related to reform of the 510(k) approval process for medical devices.
Implementation of PPACA, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate